AVDL - UBS lowers Jazz to neutral cites potential competition from Avadel drug
2023-11-27 13:44:41 ET
More on Jazz Pharmaceuticals
- Jazz Pharmaceuticals PLC (JAZZ) Q3 2023 Earnings Call Transcript
- Jazz Pharmaceuticals plc 2023 Q3 - Results - Earnings Call Presentation
- Jazz Pharma: Playing The High Notes With Xywav
- Jazz Pharma enters collaboration to develop neurological drugs
- Jazz Pharmaceuticals Q3 2023 Earnings Preview
For further details see:
UBS lowers Jazz to neutral, cites potential competition from Avadel drug